Ofir Goldberger

Professional Education

• Doctor of Philosophy, Weizmann Institute Of Science (2007)
• M.Sc., Weizmann Institute of Science Life Sciences (2002)
• B.Sc., Tel-Aviv University Life Sciences (1999)

Faculty Advisor

• Mark Davis

Web Site Links

• The Mark M. Davis lab site

Research Interests

1. A system’s biology experimental approach towards construction of immunological networks though high throughput assays.
2. Understanding T cells’ sensitivities to cytokine stimulation.

Publications

• Exuberated numbers of tumor-specific T cells result in tumor escape. Goldberger O,  Volovitz I, Machlenkin A, Vadai E, Tzehoval E, Eisenbach L.  Cancer Res.  2008; 68 (9): 3450-7
• Towards a cytokine-cell interaction knowledgebase of the adaptive immune system. Shen-Orr SS,  Goldberger O, Garten Y, Rosenberg-Hasson Y, Lovelace PA, Hirschberg DL, Altman RB, Davis MM, Butte AJ.  Pac Symp Biocomput.  2009; 439-50
• Preventive and therapeutic vaccination with PAP-3, a novel human prostate cancer peptide, inhibits carcinoma development in HLA transgenic mice. Machlenkin A,  Azriel-Rosenfeld R, Volovitz I, Vadai E, Lev A, Paz A, Goldberger O, Reiter Y, Tzehoval E, Benhar I, Eisenbach L.  Cancer Immunol Immunother.  2007; 56 (2): 217-26
• Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy. Machlenkin A,  Paz A, Bar Haim E, Goldberger O, Finkel E, Tirosh B, Volovitz I, Vadai E, Lugassy G, Cytron S, Lemonnier F, Tzehoval E, Eisenbach L.  Cancer Res.  2005; 65 (14): 6435-42
• Combined dendritic cell cryotherapy of tumor induces systemic antimetastatic immunity. Machlenkin A,  Goldberger O, Tirosh B, Paz A, Volovitz I, Bar-Haim E, Lee SH, Vadai E, Tzehoval E, Eisenbach L.  Clin Cancer Res.  2005; 11 (13): 4955-61
• In vivo rejection of tumor cells dependent on CD8 cells that kill independently of perforin and FasL. Lee SH,  Bar-Haim E, Machlenkin A, Goldberger O, Volovitz I, Vadai E, Tzehoval E, Eisenbach L.  Cancer Gene Ther.  2004; 11 (3): 237-48
• Expression of FasL by tumor cells does not abrogate anti-tumor CTL function. Lee SH,  Bar-Haim E, Goldberger O, Reich-Zeliger S, Vadai E, Tzehoval E, Eisenbach L.  Immunol Lett.  2004; 91 (2-3): 119-26